XML 13 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Preferred Stock
Paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Beginning balance at Dec. 31, 2022 $ 10,452     $ 269,626 $ (259,154) $ (20)
Beginning balance (in shares) at Dec. 31, 2022   2,175,936        
Net loss (6,954)       (6,954)  
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan (in shares)   309        
Share-based compensation expense related to issuance of stock options and RSUs, employee stock purchase plan and restricted stock awards 426     426    
Foreign currency translation adjustment 1         1
Ending balance at Mar. 31, 2023 3,925     270,052 (266,108) (19)
Ending balance (in shares) at Mar. 31, 2023   2,176,245        
Beginning balance at Dec. 31, 2022 10,452     269,626 (259,154) (20)
Beginning balance (in shares) at Dec. 31, 2022   2,175,936        
Net loss (11,135)          
Foreign currency translation adjustment 4          
Ending balance at Jun. 30, 2023 5,150     275,455 (270,289) (16)
Ending balance (in shares) at Jun. 30, 2023   2,407,796 351,037      
Beginning balance at Mar. 31, 2023 3,925     270,052 (266,108) (19)
Beginning balance (in shares) at Mar. 31, 2023   2,176,245        
Net loss (4,181)       (4,181)  
Issuance of common stock 1,953     1,953    
Issuance of common stock (in shares)   225,000        
Issuance of preferred shares 3,047     3,047    
Issuance of preferred shares ( in shares)     351,037      
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan 24     24    
Issuance of common stock upon exercise of stock options, RSUs and employee stock purchase plan (in shares)   6,618        
Share-based compensation expense related to issuance of stock options and RSUs, employee stock purchase plan and restricted stock awards 379     379    
Foreign currency translation adjustment 3         3
Fractional shares issuance   (67)        
Ending balance at Jun. 30, 2023 5,150     275,455 (270,289) (16)
Ending balance (in shares) at Jun. 30, 2023   2,407,796 351,037      
Beginning balance at Dec. 31, 2023 $ 11,288     275,717 (264,417) (12)
Beginning balance (in shares) at Dec. 31, 2023 2,474,159 2,474,159 351,037      
Net loss $ (1,542)       (1,542)  
Vesting of restricted stock awards (in shares)   25,442        
Share-based compensation expense related to issuance of stock options and RSUs, employee stock purchase plan and restricted stock awards 181     181    
Foreign currency translation adjustment (4)         (4)
Ending balance at Mar. 31, 2024 9,923     275,898 (265,959) (16)
Ending balance (in shares) at Mar. 31, 2024   2,499,601 351,037      
Beginning balance at Dec. 31, 2023 $ 11,288     275,717 (264,417) (12)
Beginning balance (in shares) at Dec. 31, 2023 2,474,159 2,474,159 351,037      
Net loss $ (2,864)          
Foreign currency translation adjustment (6)          
Ending balance at Jun. 30, 2024 $ 8,783     276,082 (267,299)  
Ending balance (in shares) at Jun. 30, 2024 2,515,874 2,515,874 351,037      
Beginning balance at Mar. 31, 2024 $ 9,923     275,898 (265,959) (16)
Beginning balance (in shares) at Mar. 31, 2024   2,499,601 351,037      
Net loss (1,322)       (1,322)  
Vesting of restricted stock awards (in shares)   16,273        
Share-based compensation expense related to issuance of stock options and RSUs, employee stock purchase plan and restricted stock awards 184     184    
Foreign currency translation adjustment (2)         (2)
Release of foreign currency translation adjustment upon liquidation of a subsidiary         (18) $ 18
Ending balance at Jun. 30, 2024 $ 8,783     $ 276,082 $ (267,299)  
Ending balance (in shares) at Jun. 30, 2024 2,515,874 2,515,874 351,037